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Summary
We examined new users of osteoporosis drugs among seniors in Pennsylvania and found no
evidence of healthy adherer bias on observed associations between adherence to treatment and
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non-vertebral fracture risk; we document fracture reduction with better adherence to
bisphosphonates, yet no fracture reduction with better adherence to calcitonin or raloxifene.
Introduction—We examined the potential for “healthy adherer bias” when studying the effects
of adherence to osteoporosis pharmacotherapy on fracture risk. Based on clinical trial evidence,
bisphosphonates, calcitonin, and raloxifene reduce vertebral fracture risk; yet only
bisphosphonates are documented to reduce non-vertebral fracture risk.
Methods—This is a cohort study of older women in Pennsylvania who initiated osteoporosis
drugs between 1995 and 2005. We included new users of bisphosphonates, calcitonin, and
raloxifene. Adherence was categorized based on a measure of compliance as high [proportion of
days covered (PDC) ≥ 80%], intermediate (50% < PDC < 80%), or low (PDC ≤ 50%) according
to a 180-day ascertainment period. Non-vertebral fracture rates within 365 days after the
ascertainment period were compared between adherence categories (reference = low) using Cox
proportional hazard models and adjusting for fracture risk factors. Primary and secondary
prevention cohorts were examined separately. Adherence to calcitonin and ralox-ifene were
control analyses.
Results—We found little difference in fracture rates between levels of adherence to calcitonin,
bisphosphonates for primary prevention, or raloxifene for secondary prevention. We document
lower fracture rates among high versus low adherent bisphosphonate users for secondary
prevention (HR = 0.53, 95%CI = 0.38–0.74) and higher fracture rates among high versus low
adherent raloxifene users for primary prevention (HR = 2.01, 95% CI = 1.04–3.87).
Conclusions—We document little evidence of healthy adherer bias when studying the
association between better adherence to osteoporosis drugs and fracture risk reduction, with only
better adherence to bisphosphonates reducing fracture risk. The higher fracture risk among highly
adherent raloxifene users for primary prevention is likely due to residual confounding.
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Introduction
Osteoporosis is an important public health problem resulting in considerable fracture-related
morbidity [1]. Several effective pharmacologic options exist to prevent fractures among
those at high risk [2], yet fewer than half of patients treated with osteoporosis drugs adhere
to therapy [3]. Prior studies that examine healthcare utilization data have found a strong
positive association between better adherence to osteoporosis pharmacotherapy and fracture
prevention [3–7]. These findings underscore the importance of interventions to improve
treatment adherence. However, these observed positive effects may also arise, in part, from
“healthy adherer bias.” Healthy adherer bias is a type of selection bias that occurs when
adherence to therapy is associated with healthy patient characteristics that are not available
in healthcare utilization data sources [8, 9]. For example, if patients who adhere to
osteoporosis pharmacotherapy are also more likely to engage in physical activity or take
over-the-counter calcium and vitamin D, then the protective effects of physical activity and
vitamin supplementation may be falsely attributed to adherence to osteoporosis
pharmacotherapy. Recent analysis of the placebo arm of the Women’s Health Initiative trial
also identifies that better adherence to placebo reduced hip fracture risk [10]. Accurate
estimates of the benefits of medication adherence are important for the cost effectiveness
analyses of quality improvement interventions as well as health policy decision making [11].
A recent study found no evidence of healthy adherer bias in explaining survival after acute
myocardial infarction, with only adherence to medications of proven mortality benefits
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(statins and β-blockers but not calcium channel blockers) being associated with survival
[12]. Although these findings support the importance of maximizing adherence to therapy
post-myocardial infarction, secondary prevention with pharmaceuticals may not be
susceptible to healthy adherer bias because patients may generally be more motivated to
adhere to therapy and engage in protective behaviors following an acute event [13–15].
Healthy adherer bias may be more likely to influence studies that examine adherence to
medication for primary prevention of an asymptomatic condition, such as osteoporosis
treatment to prevent fractures.
Our main objective was to examine the potential for healthy adherer bias in studies that
examine the effect of adherence to osteoporosis drugs on fracture prevention. We compared
adherence to different osteoporosis drug classes (bisphosphonates, nasal calcitonin,
raloxifene) and subsequent fracture risk. Although each drug class is proven effective in
reducing vertebral fracture risk, only the bisphosphonates alendronate and risedronate have
good evidence to suggest that they also reduce non-vertebral fracture risk—such as hip
fracture risk [2]. Therefore, based on clinical trial evidence, in the absence of healthy
adherer bias, adherence to calcitonin and raloxifene would not be associated with non-
vertebral fracture prevention. To better understand the potential for healthy adherer bias
when studying the association between adherence to therapy and fracture prevention, we
examined primary prevention and secondary prevention cohorts separately. We
hypothesized that adherence to therapy for primary prevention would be more susceptible to
healthy adherer bias than adherence to therapy for secondary prevention. We therefore
expected to see stronger associations between adherence to drugs with no proven benefit
(calcitonin and raloxifene) in preventing non-vertebral fractures in primary prevention than
in secondary prevention cohorts.
Materials and methods
Study cohort
The study population was identified from pharmaceutical claims for enrollees in the
Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). This state-wide
program provides drug coverage without restriction for low-income residents aged 65 or
more years with annual household income above the Medicaid threshold. We studied three
separate cohorts of new users identified from pharmacy claims between July 1, 1995 and
March 31, 2005: (1) oral bisphosphonates [alendronate (5, 10, 35, and 70 mg), risedronate (5
and 35 mg)], (2) nasal calcitonin, and (3) raloxifene. The first relevant dispensing since July
1, 1995 identified the prescription index date. New use was defined as having no use of any
bisphosphonate, calcitonin, or raloxifene in the 365 days prior to index date. Study
eligibility was limited to female patients with one or more claims in both Medicare and
PACE in each of the three 6-month intervals preceding the index date. This was to ensure
complete drug coverage and Medicare coverage during the 1-year baseline (lookback)
period used to define covariates and prior use of osteoporosis medication. In particular, we
were concerned that requiring pharmacy claims only within the two preceding 6-month
intervals would only ensure complete coverage to 6 months and 1 day prior to index date.
Given our objective of studying healthy adherer bias, it was important to limit our study to
incident users identified as no use within the 1-year lookback period. Nursing home
residents, for whom prescription data may not be complete, and patients with a Medicare
claim for Paget’s diagnosis (ICD-9-CM 731.0) were excluded. We also excluded patients
taking combination therapy, defined by a dispensing of more than a single osteoporosis
agent on the initiation date. We planned to include patients treated with ibandronate and
exclude those treated with teriparatide; however, no such patients were identified. Our data
included all PACE beneficiaries that met eligibility criteria. At the time of analysis, we had
complete Medicare data from January 1, 1994 through to December 31, 2005.
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Cohorts were subdivided into primary and secondary prevention according to diagnostic
codes identified within the year prior to treatment initiation. We classified patients as being
treated for secondary prevention if they had a diagnostic code for fracture (ICD-9-CM codes
733.1x, 800. xx–829.xx) in the prior year.
Adherence
We defined adherence to therapy based on pharmacy claims according to an ascertainment
period of 180 days. Prior evidence suggests that non-adherence to osteoporosis drugs occurs
shortly after treatment initiation and is relatively stable thereafter [3]. We examined
adherence using a measure of compliance [4], classified based on the proportion of days
covered (PDC) into: low (PDC ≤ 50%), medium (50% < PDC < 80%), and high compliance
(PDC ≥ 80%). PDC is calculated as the total number of days supplied in the observation
period, divided by the total number of days in the observation period, and capped to 1% or
100% and is therefore synonymous with the medication possession ratio (MPR) capped at
100%. The International Society for Pharmacoeconomics and Outcomes Research
recognizes both PDC and MPR, yet does not recommend the use of one term over the other
[16, 17]. We use PDC in our study because we believe that “proportion of days covered”
more clearly describes what is being measured, and in the literature, PDC is consistently
capped at 1% or 100% [18].
A cut point of ≥80% has commonly been used as an indicator of high/good compliance in
primary or secondary analyses that examined the impact of adherence to bisphosphonates on
fracture risk [4]. However, there is less consistency in defining low compliance. We selected
≤50% as the indicator for low compliance, which, over a 180-day ascertainment period,
corresponds to fewer than 3 months of treatment—the length of time suggested before
bisphosphonates are effective in reducing non-vertebral fracture risk [19]. To account for
potential immeasurable time bias [20], we subtracted the number of days in hospital
(including long-term care) from the denominator (PDC = total days supply/[total number of
days evaluated – number of days in hospital], with a maximum of 1.0). We also excluded
patients having 50% or more days in hospital during the ascertainment period, patients who
switched therapies during the ascertainment period, and those experiencing a hip, humerus,
radius, or ulna fracture during the ascertainment period. Switching between bisphosphonates
was not considered a switch. We acknowledge that some patients may discontinue
medication if it is poorly tolerated. Regardless of the reason for treatment discontinuation,
we assumed that patients required pharmacotherapy and thus would ideally return to their
physician for a new medication in the context of adverse drug effects or poor drug tolerance.
Outcomes
Our primary outcome was non-vertebral fracture (hip, humerus and radius or ulna) within
365 days after the adherence ascertainment period (Fig. 1). We defined fractures using
previously validated criteria requiring diagnostic and procedural codes: occurring in hospital
and within 7 days for hip fracture or any diagnostic and relevant procedural code occurring
within 30 days for fractures of the humerus, radius, and ulna [21, 22]. These codes have
been validated against medical records as the reference standard, with an estimated
sensitivity of at least 90% [21]. We examined hip fracture, the most costly consequence of
untreated osteoporosis, as a secondary outcome. Observation time began after the adherence
ascertainment period, to a maximum of 365 days of follow-up (Fig. 1).
To test the hypothesis that osteoporosis medication adherence is a marker of health-seeking
behaviors, we examined the association between adherence to therapy and subsequent
vaccination (influenza and pneumoccocal) and non-osteoporosis-related preventive
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healthcare testing [mammography and Papanicolaou (PAP) testing]. Diagnostic and
procedural codes for each follow-up event are summarized in Table 3 in Appendix.
Covariates
Patient demographics were determined at the time of index prescription and other variables
by medical and pharmacy claims within the year prior to index prescription date. In our
main analysis of fracture risk, we controlled for potential confounding by including factors
plausibly related to fracture risk, such as age, prior fracture, comorbidity, and prior drug use
(Table 4 in Appendix). Covariates included in the adjusted analysis for vaccination and
preventive healthcare testing outcomes included: age groups, hospitalization, comorbidity
score quartiles, and number of drugs during the 365-day period prior to treatment initiation
categorized into quintiles, as well as respective vaccination or testing during the 365-day
baseline period and the 180-day adherence ascertainment period.
Statistical analysis
We used Cox proportional hazard models to compare event rates between levels of
adherence, adjusting for risk factors for fracture. Observation time began after the 180-day
ascertainment period and ended on the first of death date, 365 days of follow-up, or
December 31, 2005. All rates were expressed as the number of events per 100 person-years.
We tested proportional hazard assumptions by including an interaction term between
exposure and the log of time. No violations of the proportional hazard assumptions were
identified except for secondary prevention with bisphosphonates and hip fracture risk among
those in the intermediate adherence group.
The Partners HealthCare Institutional Review Board approved this project. Data Use
Agreements are in place from the Centers for Medicare and Medicaid Services and PACE.
Results
We identified 32,697 (20,205 bisphosphonate, 9,054 calcitonin, and 3,438 raloxifene)
eligible new users between July 1, 1995 and March 31, 2005 (Fig. 3 in Appendix).
Bisphosphonate users had a mean age of 79 years (SD = 6.3), calcitonin users a mean age of
81 years (SD = 6.7), and raloxifene users a mean age of 77 years (SD = 6.4). Table 1
summarizes cohort characteristics by drug class and level of adherence. The proportion
within each level of adherence was similar between primary and secondary prevention
cohorts (data not shown). Patients in high adherence groups tended to have a higher
prevalence of osteoporosis and more often had used statins, mammography, and bone
mineral density (BMD) testing.
Adjusting for covariates, better adherence to bisphosphonates significantly reduced the risk
for non-vertebral fractures (high versus low adherence HR = 0.53, 95%CI = 0.38–0.74), and
hip fracture specifically (high versus low adherence HR = 0.44, 95%CI = 0.27–0.70) among
the secondary prevention cohort. However, no evidence of fracture benefit was observed
among the primary prevention cohort of new bisphosphonate users (Table 2). We also
document little difference in fracture rates between levels of adherence to calcitonin
(primary or secondary prevention) or raloxifene for secondary prevention. Contrary to our
hypothesis that we would document lower rates of fracture with better adherence to
raloxifene for primary prevention, we document significantly higher rates of non-vertebral
fractures among high versus low adherent raloxifene users (adjusted HR = 2.01, 95%CI =
1.04–3.87) (Table 2).
When considering rates of vaccination and preventive health screening, we generally
document higher rates among high compared to low adherent users (Fig. 2). In each case,
Cadarette et al. Page 5













high adherent users were more likely to have vaccinations for influenza and pneumonia and
were also more likely to have mammography and PAP testing, with hazard ratios
consistently >1 compared to patients with low adherence. However, differences were only
statistically higher among bisphosphonate users—for whom we had more patients for
comparison (Fig. 2).
Discussion
We document that better adherence to bisphosphonates lowered non-vertebral fracture risk
among those with prior fracture and observed no evidence of fracture reduction with better
adherence to calcitonin or raloxifene (primary or secondary prevention). These data do not
support our hypothesis that healthy adherer effects bias the association between better
adherence to osteoporosis pharmacotherapy and fracture risk because our results are
consistent with trial evidence. Rather, our result corroborate a recent meta-analysis that finds
similar effect estimates between better adherence to bisphosphonates as documented in non-
experimental studies to drug effects reported in clinical trials [5].
Contrary to expected, we document an increased risk for non-vertebral fracture with better
adherence to raloxifene for primary prevention. We believe that this finding may be related
to the heterogeneity of risk among patients who are prescribed osteoporosis
pharmacotherapy for primary prevention. Osteoporosis guidelines recommend treatment to
prevent osteoporosis; however, clinical trials document fracture prevention among those
with osteoporosis or low BMD [2]. Therefore, treatment among those without low BMD
may not be effective in reducing fracture risk. Prior evidence also suggests that raloxifene
users are healthier and have lower risk for fracture compared with bisphosphonate users [22,
23]. Raloxifene users may therefore be prescribed more often at higher levels of BMD than
patients treated with bisphosphonates. Patients with a better understanding of their clinical
need for treatment based on BMD test results also adhere better to therapy [24]. Indeed, we
document that osteoporosis diagnosis was more frequent among the high versus low
adherence groups. Our observation that better adherence to raloxifene for primary
prevention is associated with increased fracture risk is likely due to residual confounding,
i.e., in primary prevention, patients with better adherence to raloxifene may have a higher
background risk for fracture that is not adequately measured by healthcare utilization data.
Our findings of no benefit for primary prevention with bisphosphonatesmay seemin contrast
to the FOSIT Study that identified non-vertebral fracture reduction with alendronate versus
placebo among postmenopausal women with lumbar spine BMD T-score ≤ −2 SD, yet
otherwise healthy [19]. However, as stated above, osteoporosis guidelines recommend
treatment to prevent osteoporosis, yet clinical trials document fracture prevention among
those with osteoporosis or low BMD [2]. Our finding may therefore suggest that
bisphosphonate do not prevent fractures among those without low BMD. Alternatively,
similar to our hypothesis that patients with better adherence to raloxifene have a higher
background risk for fracture that is not adequately measured by healthcare utilization data,
our results may reflect residual confounding. Unfortunately, we do not have BMD data to
test our hypothesis that patients with high adherence to osteoporosis pharmacotherapy for
primary prevention have lower BMD compared to patients with low adherence. We
therefore encourage caution in the interpretation of our results that examine the association
between level of adherence to osteoporosis pharmacotherapy and non-vertebral fracture risk
for primary prevention. Better understanding of fracture reduction among bisphosphonates
for primary prevention, as well as characteristics of people with high versus low levels of
adherence to osteoporosis medications, is needed.
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We recently identified a positive association between adherence to statin therapy and future
vaccination (influenza or pneumonia) rates as well as breast, prostate, or colon cancer
screening rates [25]. This finding provides some evidence that patients who adhere to statins
are also more likely to use preventive health services. Another recent study identified that
adherent statin users had lower rates of outcomes that should not be causally affected by
statin exposure, such as workplace and motor vehicle accidents [26]. In our current analysis,
we also document that highly adherent patients were more likely to use preventive
healthcare (vaccinations and preventive screening tests) than patients with low adherence.
Our data therefore support the notion that patients who adhere to preventive
pharmacotherapy for asymptomatic conditions are different in many ways from patients who
do not adhere to treatment. We are limited to healthcare utilization data and therefore cannot
comment on other potential differences between high versus low adherence groups, such as
differences in exercise, diet, calcium/vitamin D supplementation, cigarette smoking, or
alcohol intake.
Nonetheless, we document little evidence of bias due to healthy adherer effects on fractures,
the clinically relevant outcome in osteoporosis. Our data therefore suggest that fracture risk
among frail seniors may be an outcome that is not strongly related to healthy behaviors.
Alternatively, our data may add to literature suggesting that there is little evidence to support
healthy adherer bias in secondary prevention of fractures. Prior evidence suggests that
patients fail to associate fracture with underlying osteoporosis or future fracture risk [27,
28]. Data also identify that over half of women treated with osteoporosis pharmacotherapy
have vitamin D deficiency [29]. However, the same study found that lack of exercise,
absence of discussion with a physician regarding the importance of vitamin D to bone
health, and education less than grade 12 were independently associated with vitamin D
inadequacy [29]. If exercise, better communication with a physician regarding the
importance of osteoporosis pharmacotherapy, and higher education are also associated with
better adherence, then the association between better adherence to osteoporosis
pharmacotherapy and fracture reduction may be partly attributed to residual confounding
related to healthy adherer bias. It has also become clearer that calcium and vitamin D
supplementation may reduce fracture risk through improvements in BMD and reduced risk
of falls [30]. Therefore, further study is needed to clarify our findings that suggest little
evidence of healthy adherer bias when studying the association between better adherence to
osteoporosis pharmacotherapy and fracture risk reduction.
In addition to those already mentioned, three study limitations are worth noting. First, recent
evidence identifies that many patients who discontinue osteoporosis pharmacotherapy
reinitiate treatment after an extended gap in therapy [31, 32]. However, these studies defined
a minimum gap length of 60 or 105 days, and we had complete drug data that documented
no use within the previous 365 days. Evidence also suggests that the longer the period of
time without therapy, the less likely a patient is to return to treatment [18]. Therefore,
although it is possible that some patients included in our study had previously used
osteoporosis drugs, we estimate that there would be few.
Second, we may have misclassified some women when dividing our sample into cohorts of
primary and secondary prevention. We defined secondary prevention as any fracture
diagnosis within the year prior to treatment initiation. We used this definition because we
were most interested in studying the concept of healthy adherer bias and hypothesized that
patients who had experienced a fracture within the year prior to treatment initiation would
generally be more motivated to adhere to osteoporosis pharmacotherapy compared to an
asymptomatic cohort. However, some women that we categorized in the primary prevention
cohort may be more correctly classified as having being treated for secondary prevention
with prior fracture occurring before the year prior to treatment initiation. This
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misclassification may have contributed to residual confounding among the primary
prevention cohort, with women having had a fracture and misclassified as being treated for
primary prevention, also being more likely to adhere to pharmacotherapy. Unfortunately, we
are limited to a 1-year baseline period to identify fracture history and thus cannot examine
potential misclassification based on fracture history occurring more than a year prior to
treatment initiation.
Third, although we identify no evidence of healthy user bias when studying the impact of
adherence to osteoporosis medication on fracture risk reduction, our results may not
generalize to other populations. We studied a cohort of older frail women in whom there
may be less room for healthy adherer bias because the range of fracture risk may be smaller
than in a general population of younger new users (spectrum effect). We were also limited to
a small number of raloxifene users, particularly for secondary prevention—that translated
into few fracture and thus limited ability to identify differences in fracture risk between
levels of adherence for secondary prevention.
Future study is warranted to more closely examine potential healthy adherer effects when
studying the relationship between bisphosphonate adherence and fracture reduction in other
populations. In fact, recent analysis of the placebo arm of the Women’s Health Initiative
trial identifies an association between better adherence to placebo and hip fracture reduction
(HR = 0.50, 95%CI = 0.32, 0.79) [10]. Therefore, although our results find little evidence of
bias due to healthy adherer effects in a study of the effects of osteoporosis drugs on fracture
risk, we cannot comment on potential healthy adherer effects on fracture risk attributed to
better adherence to non-osteoporosis drugs. In addition, although relying on healthcare
utilization data to study the effects of adherence to osteoporosis medications on fracture risk
may not be confounded by healthy adherer bias in our study, this does not mean that healthy
adherer bias may not be of concern when studying adherence to osteoporosis medications on
other outcomes. Evidence from placebo arms of clinical trials identify that better adherence
to placebo reduces mortality [8, 9] and fracture risk [10]. These data clearly support the
concept of healthy adherer bias. A further study that considers different patient populations
and different outcomes is important. We therefore suggest caution in the interpretation of
our results in light of caveats highlighted and encourage more research to study potential
healthy adherer bias.
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Study design. *Index date; at the time of analysis, we had complete Medicare data from
January 1, 1994 through to December 31, 2005. Inclusion was limited to those with at least
one Medicare and pharmacy claim in each of the three 6-month intervals prior to treatment
initiation (system activity); therefore, July 1, 1995 is the first possible date of treatment
initiation. Baseline period: 1-year lookback to define new users and to assess covariates.
Adherence ascertainment period: Eligibility restricted to new users with complete drug
coverage during the ascertainment period (drug coverage, survive, community-dwelling).
Patients experiencing a hip, humerus, radius, or ulna fracture or spending 50% or more days
in hospital during the ascertainment period were excluded. Adherence based on a measure of
compliance and calculated as proportion of days covered, adjusting for number of days in
hospital [20] = total days supply/(total number of days evaluated – number of days in
hospital); capped at 1.0. Follow-up for outcome assessment: maximum length of follow-up
was 365 days from the end of the 180-day ascertainment period or December 31, 2005
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Adjusted risk (hazard ratio and 95% confidence intervals) for non-vertebral fracture and
preventive healthcare services for highly adherent versus low adherent users of oral
bisphosphonates, calcitonin and raloxifene in primary prevention (a) and secondary
prevention (b) cohorts. FX hip, humerus, radius, or ulna fracture (adjusts for fracture risk
factors), HIP hip fracture (adjusts for fracture risk factors), FLU influenza vaccination
(adjusts for age, hospitalization, comorbidity, number of drugs, and prior influenza
vaccinations), PNE pneumoccocal vaccination (adjusts for age, hospitalization, comorbidity,
number of drugs and prior pneumoccocal vaccination), MAM mammography (adjusts for
age, hospitalization, comorbidity, number of drugs, and prior mammography), PAP
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Papanicolaou testing (adjusts for age, hospitalization, comorbidity, number of drugs, and
prior PAP testing)
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Flow diagram of participant inclusion—enrollees in the Pennsylvania Pharmaceutical
Assistance Contract for the Elderly (PACE). *subcategories for exclusion are not mutually
exclusive
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Table 3
Study outcome coding (diagnostic and procedural codes)
Variable Definition
Primary outcomea
    Hip fracture ICD-9-CM diagnostic codes: 820.xx, 733.14 during hospitalization AND at least one of the following
procedural codes during the same hospitalization AND within 7 days of the diagnostic code, ICD-9-CM
procedural codes: 78.55, 79.05, 79.15, 79.25, 79.35, 79.65; CPT-4 codes 27230–27248
Secondary outcome
    Hip, humerus, radius, or ulnaa Hip (defined above) Humerus: ICD-9-CM diagnostic codes: 812.xx, 733.11 AND at least one of the
following procedural codes within 30 days of the diagnostic code, ICD-9-CM procedural codes: 78.52,
79.01, 79.11, 79.21, 79.31, 79.61, CPT-4 codes 23600, 23605, 23610, 23615, 23620, 23625, 23630, 23665,
23670, 23675, 23680, 24500, 24505, 24506, 24510, 24515, 24530, 24531, 24535, 24536, 24538, 24540,
24542, 24545, 24560, 24565, 24570, 24575–24581, 24583, 24585–24588, 24516 Radius, ulna: ICD-9-CM
diagnostic codes: 813.xx, 733.12 AND at least one of the following procedural codes within 30 days of the
diagnostic code, ICD-9-CM 78.53, 79.02, 79.12, 79.22, 79.32, 79.62; CPT-4 codes 24620, 24625, 24635,
24650, 24655, 24660, 24665, 24666, 24670, 24675, 24680, 24685, 25500, 25505, 25510, 25515, 25530,
25535, 25540, 25545, 25560, 25565, 25570, 25575, 25600, 25605, 25610, 25611, 25615, 25620, 25650
Control outcome—preventive healthcare services (vaccinations)
    Influenza HCPCS code G0008; CPT-4 codes 90655, 90656, 90657, 90658, 90660; ICD-9-CM code V04.81
    Pneumoccocal HCPCS code G0009; CPT-4 code 90732
Control outcome—preventive healthcare services (screening)
    Papanicolaou (PAP) testing HCPCS codes G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091;
ICD-9-CM codes V76.2, V76.47
    Mammography HCPCS codes G0202, G0203, G0204, G0206; CPT-4 codes 76082, 76083, 76092, 76090, 76091, 3014F;
ICD-9-CM codes V76.1x)
CPT-4 Current Procedural Terminology, 4th edition; HCPCS Healthcare Common Procedure Coding System; ICD-9-CM International
Classification of Diseases, Ninth Revision, Clinical Modification
a
Validated codes[21] updated to include new codes, e.g., that replace previously validated codes
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Table 4
Coding of covariates in baseline period—all included when studying fracture risk
Variable Definition Coding
Medicare enrolment information at time of index prescription
  Age Age in years Categorical, groupings: 65–69,
70–74, 75–79, 80–84, 85–89,
and 90 or more years
  Race Caucasian race Dichotomous (yes/no)
Medicare claims within 365 days prior to index osteoporosis drug prescription
  Hospitalization within prior year Any Dichotomous (yes/no)
  Comorbidity score Charlson comorbidity score (17, 18) Ordinal (quartiles, 3 dummies)
Osteoporosis related
  Osteoporosis ICD-9-CM: 733.0x Dichotomous (yes/no)
  Kyphosis ICD-9-CM: 737.1x, 737.41, 737.3x Dichotomous (yes/no)
  Prior fracture—vertebral Vertebral (ICD-9-CM: 733.13, 805.xx) Dichotomous (yes/no)
  Prior fracture—non-vertebral Hip (ICD-9-CM: 820.xx, 733.14), humerus (ICD-9-CM:
812.xx, 733.11), and/or radius/ulna (ICD-9-CM: 813.xx,
733.12)
Dichotomous (yes/no)
  Prior fracture—other Any fracture (ICD-9-CM: 733.1x, 800.xx-829.xx) other
than vertebral / non-vertebral defined above
Dichotomous (yes/no)
Comorbidities
  Alzheimer’s/other dementia ICD-9-CM: 290.xx, 294.xx, 330.xx, 331.xx Dichotomous (yes/no)
  Asthma/chronic obstructive pulmonary disease ICD-9-CM: 493.xx, 490, 491.xx, 492.xx, 494.xx,
496.xx, 506.4x
Dichotomous (yes/no)
  Cataracts ICD-9-CM: 366.xx Dichotomous (yes/no)
  Crohn’s/gastroenteritis ICD-9-CM: 555.xx, 556.xx, 558.xx Dichotomous (yes/no)
  Depression ICD-9-CM: 293.83, 296.2x. 296.3x, 298.0x, 300.4x,
309.0x, 309.1x, 309.28, 311.xx
Dichotomous (yes/no)
  Diabetes mellitus ICD-9-CM: 1 hospitalization discharge of 250.xx or 2
outpatient claims with 250.xx
Dichotomous (yes/no)
  Falls history, syncope, or gait abnormality ICD-9-CM: E885, E885.9x, E888.xx, 780.2x, 458.0x,
781.2x, 782.3x
Dichotomous (yes/no)
  Hyperthyroidism ICD-9-CM: 242.0x-242.9x Dichotomous (yes/no)
  Hyperparathyroidism ICD-9-CM: 252.0x Dichotomous (yes/no)
  Ischemic stroke ICD-9-CM: 434.xx, 436.xx Dichotomous (yes/no)
  Liver disease ICD-9-CM: 571.4x, 571.6x, 571.8x, 571.9x, 573.xx,
070.xx
Dichotomous (yes/no)
  Malignant neoplasm ICD-9-CM: 140.xx-208.xx Dichotomous (yes/no)
  Overweight or obese ICD-9-CM: 278, 278.0x Dichotomous (yes/no)
  Parkinson’s ICD-9-CM: 332.xx, 333.0x or use of antiparkinsonian
drug
Dichotomous (yes/no)
  Renal disease ICD-9-CM: 250.4x, 403.xx, 404.02, 404.03, 404.12,
404.13, 404.92, 404.93
Dichotomous (yes/no)
  Rheumatoid arthritis ICD-9-CM: 714.xx Dichotomous (yes/no)
Pharmacy claims within 365 days prior to index osteoporosis drug prescription
Number of generics Count Ordinal (quintiles, 4 dummies)
Anti-epileptic Any pharmacy claim Dichotomous (yes/no)
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Variable Definition Coding
Beta-blocker Any pharmacy claim Dichotomous (yes/no)
Benzodiazepines Any pharmacy claim Dichotomous (yes/no)
Gastroprotective Any pharmacy claim Dichotomous (yes/no)
Glucocorticoids Any pharmacy claim Dichotomous (yes/no)
Hormone therapy Any pharmacy claim Dichotomous (yes/no)
Selective Cox-2 inhibitor Any pharmacy claim Dichotomous (yes/no)
Other nonsteroidal anti-inflammatory drug Any pharmacy claim Dichotomous (yes/no)
Selective serotonin reuptake inhibitors (SSRI) Any pharmacy claim Dichotomous (yes/no)
Non-SSRI antipsychotic Any pharmacy claim Dichotomous (yes/no)
Statin therapy Any pharmacy claim Dichotomous (yes/no)
Thiazide diuretic Any pharmacy claim Dichotomous (yes/no)
Thyroid drugs Any pharmacy claim Dichotomous (yes/no)
Miscellaneous sleep/hypnotic/barbiturates Any pharmacy claim Dichotomous (yes/no)
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